Clinical Trial Update: Phase I Trial of Silymarin for Chronic Liver Diseases [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase I study of silymarin for chronic liver diseases, including hepatitis C and non-alcoholic fatty liver disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Silymarin (silymarin)

Snippet

Sponsor: National Center for Complementary and Integrative Health (NCCIH) | Conditions: Hepatitis C, Non-Alcoholic Fatty Liver Disease | Phase 1 | Status: COMPLETED